137 related articles for article (PubMed ID: 37036596)
1. Immune checkpoint inhibitor-associated thrombosis in patients with bladder and kidney cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group.
Sánchez Cánovas M; Fernández Garay D; Adoamnei E; Guirao García E; López Robles J; Cacho Lavin D; Martínez de Castro E; Campos Balea B; Garrido Fernández A; Fernández Pérez I; Ferrández Arias A; Suarez N; Quintanar Verduguez T; Lobo de Mena M; Rodríguez L; Gutierrez D; Martín Fernández de Soiginie AM; García Adrián S; Ferrer Pérez AI; Delgado Heredia MJ; Muñoz Lerma A; Luque R; Mazariegos Rubí M; Rúperez Blanco AB; García Escobar I; Mendiola J; Muñoz Martín AJ
Clin Transl Oncol; 2023 Oct; 25(10):3021-3031. PubMed ID: 37036596
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitors-associated thrombosis in patients with lung cancer and melanoma: a study of the Spanish society of medical oncology (SEOM) thrombosis and cancer group.
Cánovas MS; Garay DF; Moran LO; Pérez JR; Rubio CMG; de Mena ML; Portero BO; Castro JB; Lage Y; Lavin DC; Blanco ABR; de Soignie AMMF; Perejón JZB; Colomo LJ; Boluda NB; Moreno JB; Verduguez TQ; Garrido CR; Huertas RM; Puig CFI; Martín AJM
Clin Transl Oncol; 2022 Oct; 24(10):2010-2020. PubMed ID: 35668339
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitors-associated thrombosis in patients with head and neck cancer: a study of the Spanish society of medical oncology (SEOM) thrombosis and cancer group.
Sánchez Cánovas M; Moya Hernández MÁ; Adoamnei E; Cacho Lavin D; Fernández Garay D; Quintanar Verdúguez T; Rogado Revuelta J; García Verdejo FJ; García Adrián S; Ferrer Pérez AI; Guirao García ME; López Robles J; Mendiola J; Muñoz Martín AJ
Clin Transl Oncol; 2024 Jun; ():. PubMed ID: 38907096
[TBL] [Abstract][Full Text] [Related]
4. Venous thromboembolism events in patients with advanced cancer on immune checkpoint inhibitors.
Kartolo A; Yeung C; Moffat GT; Hanna L; Hopman W; Baetz T
Immunotherapy; 2022 Jan; 14(1):23-30. PubMed ID: 34758641
[No Abstract] [Full Text] [Related]
5. Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival.
Sussman TA; Li H; Hobbs B; Funchain P; McCrae KR; Khorana AA
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33436486
[TBL] [Abstract][Full Text] [Related]
6. Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer.
Khorana AA; Palaia J; Rosenblatt L; Pisupati R; Huang N; Nguyen C; Barron J; Gallagher K; Bond TC
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36657815
[TBL] [Abstract][Full Text] [Related]
7. Thrombotic risk of platinum combination chemotherapy with and without immune checkpoint inhibitors for advanced non-small cell lung cancer: a nationwide inpatient database study.
Iwai C; Jo T; Konishi T; Fujita A; Michihata N; Matsui H; Fushimi K; Yasunaga H
Cancer Immunol Immunother; 2023 Nov; 72(11):3581-3591. PubMed ID: 37540262
[TBL] [Abstract][Full Text] [Related]
8. Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy.
Moik F; Chan WE; Wiedemann S; Hoeller C; Tuchmann F; Aretin MB; Fuereder T; Zöchbauer-Müller S; Preusser M; Pabinger I; Ay C
Blood; 2021 Mar; 137(12):1669-1678. PubMed ID: 33067632
[TBL] [Abstract][Full Text] [Related]
9. Incidence of venous thromboembolism and discriminating capacity of Khorana score in lung cancer patients treated with immune checkpoint inhibitors.
Alma S; Eloi D; Léa V; Julie C; Valérie M; Pierre G; Hilgers W; Philippe G; Christine Z; Philippe D
J Thromb Thrombolysis; 2022 Aug; 54(2):287-294. PubMed ID: 35396660
[TBL] [Abstract][Full Text] [Related]
10. Thromboembolism in Patients with Metastatic Urothelial Cancer Treated with Immune Checkpoint Inhibitors.
Sheng IY; Gupta S; Reddy CA; Angelini D; Funchain P; Sussman TA; Sleiman J; Ornstein MC; McCrae K; Khorana AA
Target Oncol; 2022 Sep; 17(5):563-569. PubMed ID: 35986816
[TBL] [Abstract][Full Text] [Related]
11. Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors.
Icht O; Darzi N; Shimony S; Jacobi O; Reinhorn D; Landman Y; Mutai R; Averbuch I; Shochat T; Spectre G; Raanani P; Rotem O; Dudnik E; Peled N; Zer A; Leader A
J Thromb Haemost; 2021 May; 19(5):1250-1258. PubMed ID: 33605020
[TBL] [Abstract][Full Text] [Related]
12. Venous Thromboembolism Is an Independent Predictor of Mortality Among Patients with Gastric Cancer.
Fuentes HE; Oramas DM; Paz LH; Wang Y; Andrade XA; Tafur AJ
J Gastrointest Cancer; 2018 Dec; 49(4):415-421. PubMed ID: 28634671
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors.
Ando Y; Hayashi T; Sugimoto R; Nishibe S; Ito K; Kawada K; Ikeda Y; Yamada S; Imaizumi K
Invest New Drugs; 2020 Aug; 38(4):1200-1206. PubMed ID: 31823160
[TBL] [Abstract][Full Text] [Related]
14. PO-05 - Incidence of venous thromboembolism (VTE) in bile duct tumors (BDT) treated with chemotherapy in ambulatory setting.
Adrián SG; de Castro EM; Olmos VP; Martín MN; Del Prado PM; Mena ML; Ramírez OR; Lavín DC; Arteaga JF; Martín AJ
Thromb Res; 2016 Apr; 140 Suppl 1():S178. PubMed ID: 27161693
[TBL] [Abstract][Full Text] [Related]
15. Clinical impact of venous thromboembolism in non-small cell lung cancer patients receiving immunotherapy.
Bjørnhart B; Kristiansen C; Asmussen J; Hansen KH; Wedervang K; Jørgensen TL; Herrstedt J; Schytte T
Thromb Res; 2023 Jan; 221():164-172. PubMed ID: 36396518
[TBL] [Abstract][Full Text] [Related]
16. Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors.
Brown JT; Liu Y; Shabto JM; Martini D; Ravindranathan D; Hitron EE; Russler GA; Caulfield S; Yantorni L; Joshi SS; Kissick H; Ogan K; Nazha B; Carthon BC; Kucuk O; Harris WB; Master VA; Bilen MA
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326170
[TBL] [Abstract][Full Text] [Related]
17. Clinical guide SEOM on venous thromboembolism in cancer patients.
Muñoz Martín AJ; Font Puig C; Navarro Martín LM; Borrega García P; Martín Jiménez M;
Clin Transl Oncol; 2014 Dec; 16(12):1079-90. PubMed ID: 25366189
[TBL] [Abstract][Full Text] [Related]
18. Venous thromboembolism risk in cancer patients receiving first-line immune checkpoint inhibitor versus chemotherapy.
Li A; May SB; La J; Martens KL; Amos CI; Flowers CR; Do NV; Brophy MT; Chitalia V; Ravid K; Gaziano JM; Fillmore NR
Am J Hematol; 2023 Aug; 98(8):1214-1222. PubMed ID: 37161855
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and Predictors of Venous Thromboembolism After Robot-Assisted Radical Cystectomy.
Elsayed AS; Ozair S; Iqbal U; Mostowy M; Jing Z; Gibson S; Durrani M; Hussein AA; Guru KA
Urology; 2021 Mar; 149():146-153. PubMed ID: 33221416
[TBL] [Abstract][Full Text] [Related]
20. Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival.
Ramos JD; Casey MF; Crabb SJ; Bamias A; Harshman LC; Wong YN; Bellmunt J; De Giorgi U; Ladoire S; Powles T; Pal SK; Niegisch G; Recine F; Alva A; Agarwal N; Necchi A; Vaishampayan UN; Rosenberg JE; Galsky MD; Yu EY;
Cancer Med; 2017 Jan; 6(1):186-194. PubMed ID: 28000388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
